UPDATE 1-U.S. FDA sets review for Amylin diabetes drug
* FDA review deadline is January 28, 2012
* Bydureon application resubmitted in July
LOS ANGELES Aug 10 (Reuters) - The U.S. Food and Drug Administration has set a Jan. 28, 2012 deadline for its review of a diabetes drug being developed by Amylin Pharmaceuticals Inc AMLN.O, Eli Lilly and Co (LLY.N) and Alkermes Inc (ALKS.O).
The companies submitted an application for the drug, Bydureon, last month after the regulatory agency declined on two separate occasions to approve it.
The FDA asked last year for more data on Bydureon's impact on the heart before deciding whether to clear it as a treatment for Type 2 diabetes.
Amylin said in early July that a trial of exenatide, the active ingredient in Bydureon, found no link between the drug and changes in heart rhythms. (Reporting by Deena Beasley. Editing by Robert MacMillan)
- Putin dissolves state news agency, tightens grip on Russia media
- North Korea says Kim's powerful uncle dismissed for 'criminal acts'
- Thai PM calls snap election, protesters want power now |
- Record cold, ice grip U.S.; more snow to blanket East
- Protesters fell Lenin statue, tell Ukraine's president 'you're next'